Invasion in follicular thyroid cancer cell lines is mediated by EphA2 and pAkt

Surgery (United States)

Volumn 152, Issue 6, 2012, Pages 1218-1224

  O'Malley, Yunxia ^a   Lal, Geeta ^a   Howe, James R ^a   Weigel, Ronald J ^a   Komorowski, Richard A ^b   Shilyansky, Joel ^a   Sugg, Sonia L ^a  

^a UNIVERSITY OF IOWA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; COMPLEMENTARY DNA; EPHRIN RECEPTOR A2; PROTEIN KINASE B; SMALL INTERFERING RNA; TYROSINE KINASE RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER PROGNOSIS; CELL STRAIN; CELL STRAIN FTC 133; CELL STRAIN FTC 238; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THYROID FOLLICULAR CARCINOMA; TISSUE MICROARRAY; WESTERN BLOTTING;

ADENOCARCINOMA, FOLLICULAR; CELL LINE, TUMOR; HUMANS; IMMUNOBLOTTING; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPHA2; RNA, SMALL INTERFERING; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84869380861     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2012.08.041     Document Type: Article

References (17)

1. C. Chougnet, M. Brassard, S. Leboulleux, E. Baudin, and M. Schlumberger Molecular targeted therapies for patients with refractory thyroid cancer Clin Oncol (R Coll Radiol) 22 2010 448 455
2. R.C. Ireton, and J. Chen EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics Curr Cancer Drug Targets 5 2005 149 157
3. M. Saji, and M.D. Ringel The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors Mol Cell Endocrinol 321 2010 20 28
4. V. Vasko, M. Saji, and E. Hardy Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer J Med Genet 41 2004 161 170
5. H. Miao, D.Q. Li, and A. Mukherjee EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt Cancer Cell 16 2009 9 20
6. N.Y. Yang, C. Fernandez, and M. Richter Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells Cell Signal 23 2011 201 212
7. A.S. Rao, P.E. Goretzki, J. Kohrle, and G. Brabant Letter Re: Id1 gene expression in hyperplastic and neoplastic thyroid tissues J Clin Endocrinol Metab 90 2005 5906
8. M.J. Demeure, C.H. Damsky, F. Elfman, P.E. Goretzki, M.G. Wong, and O.H. Clark Invasion by cultured human follicular thyroid cancer correlates with increased beta 1 integrins and production of proteases World J Surg 16 1992 770 776
9. T. Hoelting, P.E. Goretzki, and Q.Y. Duh Follicular thyroid cancer cells: a model of metastatic tumor in vitro (review) Oncol Rep 8 2001 3 8
10. M.S. Duxbury, H. Ito, M.J. Zinner, S.W. Ashley, and E.E. Whang Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness Biochem Biophys Res Commun 320 2004 1096 1102
11. T. Kondo, S. Ezzat, and S.L. Asa Pathogenetic mechanisms in thyroid follicular-cell neoplasia Nat Rev Cancer 6 2006 292 306
12. V.V. Vasko, and M. Saji Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis Curr Opin Oncol 19 2007 11 17
13. C.W. Menges, and D.J. McCance Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor Oncogene 27 2008 2934 2940
14. M. Soula-Rothhut, C. Coissard, and H. Sartelet The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells Exp Cell Res 304 2005 187 201
15. L.P. Weng, O. Gimm, and J.B. Kum Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death Hum Mol Genet 10 2001 251 258
16. E. Puxeddu, S. Romagnoli, and M.E. Dottorini Targeted therapies for advanced thyroid cancer Curr Opin Oncol 23 2011 13 21
17. R. Liu, D. Liu, E. Trink, E. Bojdani, G. Ning, and M. Xing The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway J Clin Endocrinol Metab 96 2011 E577 E585